ArticleCancer science2021
Iron chelation cancer therapy using hydrophilic block copolymers conjugated with deferoxamine.
Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 49 citations in OpenAlex.
- Iron overload in the tumor microenvironment induces CD8Nature communications · 2026Article
- Divergent effects of topical deferoxamine treatment on skin and cancer cells uncovers its potential as a safe radioprotective agent in oncological applications.Cancer cell international · 2026Article
- Desferrioxamine attenuating high glucose-induced ferroptosis and inflammatory responses in Müller glial cellsInternational journal of ophthalmology · 2026Article
- Improving Fat Graft Survival Using Soluble Molecule Preconditioning.Biomolecules · 2025Review
- Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization.Nature communications · 2025Article
- FGFR1 governs iron homeostasis via regulating intracellular protein degradation pathways of IRP2 in prostate cancer cells.Communications biology · 2024Article
- MALDI-mass spectrometry imaging as a new technique for detecting non-heme iron in peripheral tissues via caudal vein injection of deferoxamine.Analytical and bioanalytical chemistry · 2024Article
- Plumbagin induces ferroptosis in colon cancer cells by regulating p53-related SLC7A11 expression.Heliyon · 2024Article
- Chelation of Mitochondrial Iron as an Antiparasitic Strategy.ACS infectious diseases · 2024Article
- Nanoenabled Intracellular Metal Ion Homeostasis Regulation for Tumor Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Deferoxamine Mitigates Ferroptosis and Inflammation in Hippocampal Neurons After Subarachnoid Hemorrhage by Activating the Nrf2/TXNRD1 Axis.Molecular neurobiology · 2024Article
- STAT5B Suppresses Ferroptosis by Promoting DCAF13 Transcription to Regulate p53/xCT Pathway to Promote Mantle Cell Lymphoma Progression.Biologics : targets & therapy · 2024Article
- Article review: Brazilin as potential anticancer agent.Frontiers in pharmacology · 2024Review
- Depletion of Labile Iron Induces Replication Stress and Enhances Responses to Chemoradiation in Non-Small-Cell Lung Cancer.Antioxidants (Basel, Switzerland) · 2023Article
- Opportunities and challenges of microbial siderophores in the medical field.Applied microbiology and biotechnology · 2023Review
- A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer.Molecular oncology · 2023Article
- Combination Effect of Deferoxamine and Arsenic Trioxide on Viability and Vitality of APL Like Cell Line.Ethiopian journal of health sciences · 2023Article
- LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism.Nature communications · 2023Article
- Polymeric iron chelators for enhancing 5-aminolevulinic acid-induced photodynamic therapy.Cancer science · 2023Article
- Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present.Biomolecules · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 3 countries.
Funding
Abstract
Cancer cells have high iron requirements due to their rapid growth and proliferation. Iron depletion using iron chelators has a potential in cancer treatment. Previous studies have demonstrated that deferoxamine (DFO) specifically chelates Fe(III) and exhibited antitumor activity in clinical studies. However, its poor pharmacokinetics has limited the therapeutic potential and practical application. Although polymeric iron chelators have been developed to increase the blood retention, none of previous studies has demonstrated their potential in iron chelation cancer therapy. Here, we developed polymeric DFO by the covalent conjugation of DFO to poly(ethylene glycol)-poly(aspartic acid) (PEG-PAsp) block copolymers. The polymeric DFO exhibited iron-chelating ability comparable with free DFO, thereby arresting cell cycle and inducing apoptosis and antiproliferative activity. After intravenous administration, the polymeric DFO showed marked increase in blood retention and tumor accumulation in subcutaneous tumor models. Consequently, polymeric DFO showed significant suppression of the tumor growth compared with free DFO. This study reveals the first success of the design of polymeric DFO for enhancing iron chelation cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.